1,230 Shares in argenx SE (NASDAQ:ARGX) Purchased by Ethic Inc.

Ethic Inc. purchased a new stake in shares of argenx SE (NASDAQ:ARGX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,230 shares of the company's stock, valued at approximately $756,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GeoWealth Management LLC raised its stake in shares of argenx by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after purchasing an additional 18 shares during the last quarter. Whipplewood Advisors LLC purchased a new position in argenx in the 4th quarter worth about $37,000. Global Retirement Partners LLC lifted its stake in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after acquiring an additional 48 shares during the period. FIL Ltd bought a new position in argenx during the 4th quarter valued at about $38,000. Finally, Jones Financial Companies Lllp boosted its holdings in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after acquiring an additional 61 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

argenx Trading Down 0.6%

ARGX traded down $3.58 during trading on Tuesday, hitting $574.53. The company's stock had a trading volume of 88,227 shares, compared to its average volume of 323,986. The firm has a market capitalization of $35.08 billion, a price-to-earnings ratio of -652.16 and a beta of 0.57. argenx SE has a twelve month low of $356.38 and a twelve month high of $678.21. The business's fifty day simple moving average is $591.36 and its 200 day simple moving average is $613.42.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. The firm had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities research analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ARGX has been the topic of a number of research reports. Wells Fargo & Company raised their price target on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. William Blair reissued an "outperform" rating on shares of argenx in a report on Friday, February 28th. Wedbush restated an "outperform" rating and set a $715.00 price target on shares of argenx in a research note on Friday, April 11th. Robert W. Baird raised shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 price target for the company in a research report on Tuesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, argenx presently has an average rating of "Buy" and a consensus price target of $698.11.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.